New drug cocktail shows promise against rare blood cancer

This study tests whether combining two drugs, duvelisib and chidamide, can safely control peripheral T-cell lymphoma in people who are newly diagnosed. About 36 adults aged 18 to 70 will receive the combination and be monitored for side effects and how well the cancer responds. The goal is to improve remission rates and delay disease progression.